Storm Therapeutics develops small-molecule therapies that target RNA-modifying enzymes to treat cancer and other diseases.
Storm Therapeutics has raised $56.0M in total funding. The most recent round was Series C. The last funding was announced in April 2026.
Storm Therapeutics's investors include Fast Track Initiative, Inc., Taiho Ventures, UTokyo Innovation Platform, IP Group, Cambridge Innovation Capital.
Storm Therapeutics is headquartered in Cambridge, United Kingdom.
Storm Therapeutics develops small-molecule therapies that target RNA-modifying enzymes to treat cancer and other diseases.
Storm Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Storm Therapeutics — Funding & Investors." VCBacked, April 16, 2026, https://www.vcbacked.co/company/storm-therapeutics. Accessed November 12, 2026.
VCBacked. (2026). Storm Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/storm-therapeutics
{{cite web |title=Storm Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/storm-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Storm Therapeutics? Request a listing update